Advisor Group Holdings, Inc. Aerie Pharmaceuticals Inc Transaction History

Advisor Group Holdings, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$6.37 - $15.23 $75,917 - $181,511	-11,918 Reduced 78.28%	3,307 $49,000
Q2 2022 Aug 10, 2022	BUY	$4.95 - $9.16 $41,391 - $76,595	8,362 Added 121.84%	15,225 $113,000
Q1 2022 May 04, 2022	SELL	$5.64 - $9.8 $8,313 - $14,445	-1,474 Reduced 17.68%	6,863 $62,000
Q3 2021 Nov 05, 2021	BUY	$11.32 - $16.63 $19,504 - $28,653	1,723 Added 26.05%	8,337 $95,000
Q2 2021 Aug 02, 2021	SELL	$15.16 - $18.97 $8,444 - $10,566	-557 Reduced 7.77%	6,614 $106,000
Q1 2021 May 13, 2021	SELL	$13.12 - $20.9 $12,870 - $20,502	-981 Reduced 12.03%	7,171 $128,000
Q4 2020 Feb 10, 2021	SELL	$9.12 - $14.49 $86,968 - $138,176	-9,536 Reduced 53.91%	8,152 $109,000
Q3 2020 Nov 12, 2020	BUY	$10.46 - $14.46 $139,714 - $193,142	13,357 Added 308.4%	17,688 $209,000
Q2 2020 Aug 14, 2020	BUY	$12.0 - $16.13 $35,460 - $47,664	2,955 Added 214.75%	4,331 $64,000
Q1 2020 May 18, 2020	BUY	$11.84 - $25.52 $16,291 - $35,115	1,376 New	1,376 $20,000

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisor Group Holdings, Inc. with notifications on news.